Liver fibrosis as a predictor of liver failure and outcome following ALPPS among patients with primary liver cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
09 Jul 2024
Historique:
received: 18 03 2024
accepted: 25 06 2024
medline: 10 7 2024
pubmed: 10 7 2024
entrez: 9 7 2024
Statut: epublish

Résumé

The influence of liver fibrosis on the rate of liver regeneration and complications following ALPPS has yet to be fully understood. This study aimed to scrutinize the effects of liver fibrosis on the postoperative complications, and prognosis subsequent to ALPPS. Clinical data were collected from patients with primary liver cancer who underwent ALPPS at Peking Union Medical College Hospital between May 2014 and October 2022. The degree of liver fibrosis was assessed using haematoxylin-eosin staining and Sirius red staining. This study encompassed thirty patients who underwent ALPPS for primary liver cancer, and there were 23 patients with hepatocellular carcinoma, 5 with cholangiocarcinoma, and 2 with combined hepatocellular-cholangiocarcinoma. The impact of severe liver fibrosis on the rate of liver regeneration was not statistically significant (P = 0.892). All patients with severe complications belonged to the severe liver fibrosis group. Severe liver fibrosis exhibited a significant association with 90 days mortality (P = 0.014) and overall survival (P = 0.012). Severe liver fibrosis emerges as a crucial risk factor for liver failure and perioperative mortality following the second step of ALPPS. Preoperative liver function impairment is an important predictive factor for postoperative liver failure.

Identifiants

pubmed: 38982109
doi: 10.1038/s41598-024-65924-2
pii: 10.1038/s41598-024-65924-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15827

Subventions

Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-049

Informations de copyright

© 2024. The Author(s).

Références

Anwanwan, D., Singh, S. K., Singh, S., Saikam, V. & Singh, R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer 1873, 188314 (2020).
doi: 10.1016/j.bbcan.2019.188314 pubmed: 31682895
Zhou, M. et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet 394, 1145–1158 (2019).
doi: 10.1016/S0140-6736(19)30427-1 pubmed: 31248666 pmcid: 6891889
Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132 (2016).
doi: 10.3322/caac.21338 pubmed: 26808342
Fu, J. & Wang, H. Precision diagnosis and treatment of liver cancer in China. Cancer Lett. 412, 283–288 (2018).
doi: 10.1016/j.canlet.2017.10.008 pubmed: 29050983
Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).
doi: 10.1056/NEJMra1713263 pubmed: 30970190
Lang, H. et al. 10th anniversary of ALPPS-lessons learned and quo Vadis. Ann. Surg. 269, 114–119 (2019).
doi: 10.1097/SLA.0000000000002797 pubmed: 29727331
Hasselgren, K. et al. ALPPS improves survival compared with TSH in patients affected of CRLM: Survival analysis from the randomized controlled trial LIGRO. Ann. Surg. 273, 442–448 (2021).
doi: 10.1097/SLA.0000000000003701 pubmed: 32049675
Li, P. P. et al. Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma: A randomized comparative study. Hepatobiliary Surg. Nutr. 11, 38–51 (2022).
doi: 10.21037/hbsn-20-264 pubmed: 35284529 pmcid: 8847855
Chan, A. et al. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma: A changing paradigm in modulation of future liver remnant before major hepatectomy. Ann. Surg. 273, 957–965 (2021).
doi: 10.1097/SLA.0000000000003433 pubmed: 31305284
Cai, X. et al. The ALPPS in the treatment of hepatitis B-related hepatocellular carcinoma with cirrhosis: A single-center study and literature review. Surg. Innov. 24, 358–364 (2017).
doi: 10.1177/1553350617697187 pubmed: 28689487
Chia, D. K. A. et al. ALPPS for hepatocellular carcinoma is associated with decreased liver remnant growth. J. Gastrointest. Surg. 22, 973–980 (2018).
doi: 10.1007/s11605-018-3697-x pubmed: 29380118
Kambakamba, P. et al. Liver kinetic growth rate predicts postoperative liver failure after ALPPS. HPB (Oxford) 18, 800–805 (2016).
doi: 10.1016/j.hpb.2016.07.005 pubmed: 27524732
Liu, J. G. et al. ALPPS in the treatment of liver cancer with insufficient future liver remnant. Hepatobiliary Pancreat. Dis. Int. 20, 400–402 (2021).
doi: 10.1016/j.hbpd.2021.04.003 pubmed: 33952408
D’Haese, J. G. et al. Should ALPPS be used for liver resection in intermediate-stage HCC?. Ann. Surg. Oncol. 23, 1335–1343 (2016).
doi: 10.1245/s10434-015-5007-0 pubmed: 26646946
Rahbari, N. N. et al. Posthepatectomy liver failure: A definition and grading by the International study group of liver surgery (ISGLS). Surgery 149, 713–724 (2011).
doi: 10.1016/j.surg.2010.10.001 pubmed: 21236455
Feng, L. M. et al. New formula for predicting standard liver volume in Chinese adults. World J. Gastroenterol. 23, 4968–4977 (2017).
doi: 10.3748/wjg.v23.i27.4968 pubmed: 28785151 pmcid: 5526767
Zhang, J. et al. Application of associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma related to hepatitis B virus: Comparison with traditional one-stage right hepatectomy. Transl. Cancer Res. 9, 5371–5379 (2020).
doi: 10.21037/tcr-19-2633 pubmed: 35117902 pmcid: 8798876
Ishak, K. et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22, 696–699 (1995).
doi: 10.1016/0168-8278(95)80226-6 pubmed: 7560864
van den Broek, M. A. et al. Liver failure after partial hepatic resection: Definition, pathophysiology, risk factors and treatment. Liver Int. 28, 767–780 (2008).
doi: 10.1111/j.1478-3231.2008.01777.x pubmed: 18647141
Huang, Y. L. et al. Elevated intramuscular adipose tissue content with a high Ishak fibrosis stage (>3) had a negative effect on liver regeneration in cirrhotic patients undergoing portal vein embolization. Kaohsiung J. Med. Sci. 39, 182–190 (2023).
doi: 10.1002/kjm2.12622 pubmed: 36394149
Denys, A. et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J. Vasc. Interv. Radiol. 16, 1667–1674 (2005).
doi: 10.1097/01.RVI.0000182183.28547.DC pubmed: 16371534
Vennarecci, G. et al. ALPPS for primary and secondary liver tumors. Int. J. Surg. 30, 38–44 (2016).
doi: 10.1016/j.ijsu.2016.04.031 pubmed: 27112834
Wang, Z. et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: A single center study of 45 patients. Ann. Surg. 271, 534–541 (2020).
doi: 10.1097/SLA.0000000000002942 pubmed: 29995681
Reese, T. et al. Impact of acute kidney injury after extended liver resections. HPB (Oxford) 23, 1000–1007 (2021).
doi: 10.1016/j.hpb.2020.10.015 pubmed: 33191106
Tao, W., Shi, X. & Wang, G. Acute kidney injury following the first stage of the ALPPS procedure: A case report. Exp. Ther. Med. 15, 2990–2993 (2018).
pubmed: 29599836 pmcid: 5867463
Reese, T. et al. Renal impairment is associated with reduced outcome after associating liver partition and portal vein ligation for staged hepatectomy. J. Gastrointest. Surg. 24, 2500–2507 (2020).
doi: 10.1007/s11605-019-04419-2 pubmed: 31745902
Huang, H. et al. Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: Two case reports and a literature review. Ann. Transl. Med. 7, 795 (2019).
doi: 10.21037/atm.2019.11.99 pubmed: 32042811 pmcid: 6989963
Tomassini, F. et al. Hepatobiliary scintigraphy and kinetic growth rate predict liver failure after ALPPS: A multi-institutional study. HPB (Oxford) 22, 1420–1428 (2020).
doi: 10.1016/j.hpb.2020.01.010 pubmed: 32057681
Linecker, M. et al. The ALPPS risk score: Avoiding futile use of ALPPS. Ann. Surg. 264, 763–771 (2016).
doi: 10.1097/SLA.0000000000001914 pubmed: 27455156
Nwosu, Z. C. et al. Identification of the consistently altered metabolic targets in human hepatocellular carcinoma. Cell Mol. Gastroenterol. Hepatol. 4, 303-323.e301 (2017).
doi: 10.1016/j.jcmgh.2017.05.004 pubmed: 28840186 pmcid: 5560912
Rousselet, M. C. et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 41, 257–264 (2005).
doi: 10.1002/hep.20535 pubmed: 15660389
Dong, X. Q., Wu, Z., Zhao, H. & Wang, G. Q. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J. Viral Hepat. 26, 297–307 (2019).
doi: 10.1111/jvh.13031 pubmed: 30380170
Seo, Y. S. et al. Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. Liver Int. 35, 2246–2255 (2015).
doi: 10.1111/liv.12808 pubmed: 25682719
Singh, S. et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: A systematic review and meta-analysis of individual participant data. Clin. Gastroenterol. Hepatol. 13, 440-451.e446 (2015).
doi: 10.1016/j.cgh.2014.09.046 pubmed: 25305349

Auteurs

Junwei Zhang (J)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Lei Zhang (L)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Xiaobo Yang (X)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Yongchang Zheng (Y)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Haifeng Xu (H)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Shunda Du (S)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Yilei Mao (Y)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Xinting Sang (X)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.

Haitao Zhao (H)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. zhaoht@pumch.cn.

Yiyao Xu (Y)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. xuyiyao@pumch.cn.

Xin Lu (X)

Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. luxin@pumch.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH